The mode of action of treatment by IgG of haemolytic anaemia induced by an anti-erythrocyte monoclonal antibody

Clinical and Experimental Immunology

Volumn 106, Issue 1, 1996, Pages 103-107

  Pottier, Y ^a   Pierard, I ^a   Barclay, A ^b   Masson, P L ^a   Coutelier, J P ^a,c  

^a International Institute of Cellular and Molecular Pathology   (Belgium)

^b Baxter R and D Europe   (Belgium)

^c ICP 7430   (Belgium)

Author keywords

Autoimmune haemolytic anaemia; Fc receptor; Immunoglobulin; Macrophage; Phagocytosis

Indexed keywords

ERYTHROCYTE ANTIBODY; FC RECEPTOR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2A; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; CONTROLLED STUDY; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; MACROPHAGE; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL;

EID: 0029782856     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1996.d01-818.x     Document Type: Article

References (44)

1. Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med 1992; 326:107 16.
2. Masson PL. The therapeutic use of human immunoglobulin selected on the basis of their antibody activity against circulating antigens. In: Peeters H, Wright P, eds. Plasma protein pathology. Oxford: Pergamon Press. 1979:35 44.
3. Imbach P, d'Apuzzo V, Hirt A et al, High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; i:1228 30.
4. Kickler T, Braine HG, Piantadosi S et al. A randomized, placebo-controlled trial of intravenous gammaglobulin in alloimmunized thrombocytopenic patients. Blood 1990; 75:313 6.
5. Newburger JW, Takahashi M, Burns JC et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986; 315:341 7.
6. van der Meché FGA, Schmitz PIM, the Dutch Guillain Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain Barré syndrome. N Engl J Med 1992; 326:1123 9.
7. Kaveri SV, Dietrich G, Hurez V et al. Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases, Clin Exp Immunol 1991; 86:192 8.
8. Liblau R, Gajdos P, Bustarret FA et al. Intravenous γ-globulin in myasthenia gravis: interaction with anti-acetylcholine receptor autoantibodies. J Clin Immunol 1991; 11:128 31.
9. Cosi V, Lombardi M, Piccolo G et al. Treatment of myasthenia gravis with high-dose intravenous immunoglobulin. Acta Neurol Scand 1991; 84:81 84.
10. Masson PI., Elimination of infectious antigens and increase of IgG catabolism as possible modes of action of IVIg. J Autoimmun 1993; 6:683 9.
11. Nydegger UE, Sultan Y, Kazatchkine MD. The concept of antiidiotypic regulation of selected autoimmune diseases by intravenous immunoglobulin. Clin Immunol Immunopathol 1989; 53:S72 82.
12. Rossi F, Dietrich G, Kazatchkine MD. Anti-idiotypes against autoantibodies in normal immunoglobulins: evidence for network regulation of human autoimmune responses. Immunol Rev 1989; 110:135 49.
13. Rossi F, Kazatchkine MD. Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig. J Immunol 1989; 143:4104 9.
14. Rossi F, Guilbert B, Tonnelle C et al. Idiotypic interactions between normal human polyspecific IgG and natural IgM antibodies. Eur J Immunol 1990; 20:2089 94.
15. Galli M, Cortelazzo S, Barbui T. In vivo efficacy of intravenous gammaglobulins in patients with lupus anticoagulant is not mediated by an anti-idiotypic mechanism. Am J Hematol 1991; 38:184 8.
16. Kazatchkine MD, Dietrich G, Hurez V et al. V region-mediated selection of autoreaetive repertoires by intravenous immunoglobulin (i. v. Ig). Immunol Rev 1994; 139:79 107.
17. Sundblad A, Huetz F, Portnoï D et al. Stimulation of B and T cells by in vivo high dose immunoglobulin administration in normal mice. J Autoimmun 1991; 4:325 39.
18. Sundblad A, Marcos M, Huctz F et al. Normal serum immunoglobulins influence the numbers of bone marrow pre-B and B cells. Eur J Immunol 1991; 21:1155 61.
19. Sunblad A, Marcos MAR, Malanchere E et al. Observations on the mode of action of normal immunoglobulin at high doses. Immunol Rev 1994; 139:125 58.
20. Marchalonis JJ. Kaymaz H, Dedeoglu F et al. Human autoantibodies reactive with synthetic autoamigens from T-cell receptor 3 chain. Proc Natl Acad Sci USA 1992: 89:3325 9.
21. Saoudi A, Hurez V, de Kozak Y et al. Human immunoglobulin preparations for intravenous use prevent experimental autoimmune uveoretinitis. Int Immunol 1993; 5:1559 67.
22. Meissner HC, Schlievert PM, Leung DYM. Mechanisms of immunoglobulin action: observations on Kawasaki syndrome and RSV prophylaxis. Immunol Rev 1994; 139:109 23.
23. Abe Y, Horiuchi A, Miyake M et al. Anti-cylokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol Rev 1994; 139:5 19.
24. Andersson U, Björk L, Skansén-Saphir U et al. Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immunol Rev 1994; 139:21 42.
25. Arend WP, Leung DYM. IgG induction of IL-1 receptor antagonist production by human monocytes. Immunol Rev 1994; 139:71 78.
26. Dinarello CA. Is there a role for interleukin-1 blockade in intravenous immunoglobulin therapy? Immunol Rev 1994; 139:173 87.
27. Gisler RH, Fridman WH. Suppression of in vitro antibody synthesis by immunoglobulin-binding factor. J Exp Med 1975; 142:507 11.
28. Fridman WH, Teillaud JF, Amigorena S et al. The isotypic circuit: immunoglobulins, Fc receptors and immunoglobulin binding factors. Intern Rev Immunol 1987; 2:221 40.
29. Varin N, Sautès C, Galinha A et al. Recombinant soluble receptors for the Feγ portion inhibit antibody production in vitvo. Eur J Immunol 1989; 19:2263 8.
30. Lynch A, Tartour E, Teillaud JL et al. Increased levels of soluble low-affinity Feγ receptors (IgG-binding factors) in the sera of tumour-bearing mice. Clin Exp Immunol 1992; 87:208 14.
31. Debré M. Bonnet MC, Fridman WH et al. Infusion of Feγ fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 1993; 342:945 9.
32. Reininger L, Shibata T, Ozaki S et al. Variable region sequences of pathogenic anti-mouse red blood cell autoantibodies from autoimmune NZB mice. Eur J Immunol 1990; 20:771 7.
33. Shibata T, Berney T, Reininger F et al. Monoclonal anti-erythrocyte autoantibodies derived from NZB mice cause autoimmune hemolytic anemia by two distinct pathogenic mechanisms, Int Immunol 1990; 2:1133 41.
34. Cerottini JC. An antigen-binding capacity test for human immunoglobulin G (IgG) fragments. J Immunol 1968; 101:433 8.
35. Broomhall KS, Morin M, Pevear DC et al. Severe and transient pancytopenia associated with a chronic arenavirus infection. J Exp Pathol 1987; 3:259 69.
36. Vella AT, Pfau CJ. The presence of an anti-erythrocyte autoantibody in C3HeB/FeJ mice after lymphocytic choriomeningitis virus infection. Autoimmunity 1991; 9:319 29.
37. + cells in lymphocytic choriomeningitis virus-induced autoimmune anaemia and hypergammaglobulinaemia. J Autoimmun 1994; 7:589 99.
38. Fehr J, Hofmann V, Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N Engl J Med 1982; 306:1254 8.
39. Kimberly RP, Salmon JK, Bussel JB et al. Modulation of mononuclear phagocyte function by intravenous γ-globulin. J Immunol 1984; 132:745 50.
40. Oksenhendler E, Bierling P, Brossard Y et al. Anti-RH immunoglobulin therapy for human immunodeficiency virus-related immune thrombocytopenic purpura. Blood 1988; 71:1499 502.
41. Clarkson SB, Bussel JB, Kimberly RP et al. Treatment of refractory immune thrombocytopenic purpura with an anti-Feγ-receptor antibody. N Engl J Med 1986; 314:1236-9.
42. Salama A, Mueller-Eckhardt C, Kiefel V. Effect of intravenous immunoglobulin in immune thrombocytopenia. Competitive inhibition of reticuloendothelial system function by sequestration of autologous red blood cells? Lancet 1983; ii:193 5.
43. Bussel JB, Cunningham-Rundles C, Abraham C. Intravenous treatment of autoimmune hemolytic anemia with very high dose gammaglobulin. Vox Sang 1986; 51:264 9.
44. Besa EC. Rapid transient reversal of anemia and long-term effects of maintenance intravenous immunoglobulin for autoimmune hemolytic anemia in patients with lymphoproliferative disorders. Am J Med 1988; 84:691 8.